Format

Send to

Choose Destination
Contemp Clin Trials. 2011 May;32(3):428-36. doi: 10.1016/j.cct.2011.01.006. Epub 2011 Jan 20.

An evaluation of a Simon 2-Stage phase II clinical trial design incorporating toxicity monitoring.

Author information

1
Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences, University of Louisville, Louisville, KY, USA. herman.ray@louisville.edu

Abstract

Phase II clinical trials are usually designed to measure efficacy but patient safety is also a very important aspect. Previous authors suggested a methodology that allows one to monitor the cumulative number of toxic events after each patient is treated, which is also known as continuous toxicity monitoring. In this work we describe how to combine the continuous toxicity monitoring methodology with the Simon 2-Stage design for response. Then we investigate through simulation the combined procedure's type I and type II error rates under various combinations of design parameters. We include the underlying relationship between toxicity and response in our examination of the error rates.

PMID:
21256247
DOI:
10.1016/j.cct.2011.01.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center